Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020

Table 2 Therapy duration of bisphosphonates

Animal model	Short-term (≤ 2 months)			Intermediate-term (2 to 6 months)			Long term (≥6 months)
Animal model	Reference	Drug	Duration	Reference	Drug	Duration	Reference	Drug	Duration
Rabbit	She et al. [20]	ZLN	*	Shirai et al. [23]	ALN	3
	Lamproploulou et al. [21]	ZLN	1
	Permuy et al. [22]	RIS	2
	Zhang et al. [24]	ALN	2
	MacNeil et al. [25]	RIS	1.5
	Doschack et al. [26]	RIS	1.5
	Doschack et al. [27]	RIS	1.5
	Muehleman et al. [28]	ZLN	2
Rat	Cinar et al. [29]	ZLN	1.5	Bagi et al. [30]	ZLN	2.5
	Mohan et al. [32]	ALN	< 1	Zhu et al. [31]	ALN	4.5
	Panahafir et al. [33]	ALN	2	Hayami et al. [37]	ALN	2.5
	Koh et al. [34]	PAM	2
	Strassle et al. [36]	ZLN	< 1
	Jones et al. [35]	ALN/RIS	2
Mice	Adebayo et al. [38] Khorasani et al. [39]	ALN ALN	1.5 1	Sniekers et al. [40]	ALN	3
Guinea-Pig				Ding et al. [42]	ALN	4.5	Thomsen et al. [41]	RIS	6
Dog	Moreau et al. [45]	TLN	1.5	Pelletier et al. [44]	TLN	3	Dearmin et al. [43]	ZLN	12

ALN alendronate, PAM pamidronate, RIS risedronate, ZLN zoledronic acid, TIL tiludronate. Duration in months. *Only once post-surgery

ISSN: 1478-6362